Daprodustat

• Description :

  Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

• Product Name Alternative :

  GSK1278863

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  HIF/HIF Prolyl-Hydroxylase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Daprodustat.html

• Concentration :

  10mM

• Purity :

  99.91

• Solubility :

  DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(O)CNC(C(C(N1C2CCCCC2)=O)C(N(C3CCCCC3)C1=O)=O)=O

• Molecular Formula :

  C19H27N3O6

• Molecular Weight :

  393.43

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Brigandi RA, et al. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. Am J Kidney Dis. 2016 Jun;67 (6) :861-71|[2]Hara K, et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015 Dec;30 (6) :410-8

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [960539-70-2]